Eli Lilly stock sank after its second-quarter report due to underwhelming results for a key weight loss drug in its pipeline.

A UK government and Eli Lilly £85 million program will expand obesity care nationwide, offering digital, community, and ...

The obesity market still only has two clear leaders with approved GLP-1 medications, and frontrunners Eli Lilly and Novo ...

Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an ...

The two main players in the global obesity market are Eli Lilly LLY and Novo Nordisk NVO, with their respective GLP-1 ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

When Eli Lilly (LLY) posted strong quarterly results, the stock fell from $750 to $625.65 by August 8. Shareholders fretted about clinical results from its next-generation obesity drug. Its 37.7% Y/Y ...

Kinder Morgan benefits from this through a massive $9.3 billion backlog, with $1.3 billion in new projects added and $750 ...

In a phase 3 trial, the daily GLP-1 pill has shown "meaningful weight loss" and similar side effects to injectable GLP-1 drugs like Ozempic, Eli Lilly has said., Health, Times Now ...

The partnership means that Apple's fitness and wellness service will be made available to all members who enrol onto ...

Eli Lilly and Co. has already launched LillyDirect service, which CEO David Ricks says jibes with the administration’s demand ...

Peter Kyle said he wants the likes of Wegovy and Mounjaro to be 'widely used' and made 'available to everyone from every ...